Farther Finance Advisors LLC Raises Stake in Twist Bioscience Corporation (NASDAQ:TWST)

Farther Finance Advisors LLC lifted its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 18.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 6,435 shares of the company’s stock after purchasing an additional 1,006 shares during the quarter. Farther Finance Advisors LLC’s holdings in Twist Bioscience were worth $251,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of TWST. Versant Capital Management Inc lifted its position in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after acquiring an additional 580 shares in the last quarter. Van ECK Associates Corp lifted its position in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Banque Transatlantique SA acquired a new position in Twist Bioscience during the 4th quarter worth approximately $43,000. GF Fund Management CO. LTD. acquired a new position in Twist Bioscience during the 4th quarter worth approximately $58,000. Finally, US Bancorp DE lifted its position in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares in the last quarter.

Analyst Ratings Changes

TWST has been the topic of several recent research reports. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Guggenheim reissued a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Barclays reduced their price target on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. JPMorgan Chase & Co. cut their target price on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 6th. Finally, Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $50.40.

Twist Bioscience Stock Performance

TWST stock opened at $35.89 on Thursday. The company has a current ratio of 4.51, a quick ratio of 4.24 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.15 billion, a P/E ratio of -11.04 and a beta of 2.38. Twist Bioscience Corporation has a 12-month low of $27.12 and a 12-month high of $60.90. The stock’s 50 day simple moving average is $33.83 and its 200 day simple moving average is $41.33.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. As a group, equities research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 936 shares of the company’s stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $27,846.00. Following the completion of the transaction, the chief financial officer now directly owns 106,018 shares in the company, valued at $3,154,035.50. This represents a 0.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paula Green sold 1,101 shares of the company’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $41,452.65. Following the transaction, the senior vice president now owns 129,380 shares of the company’s stock, valued at approximately $4,871,157. The trade was a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,673 shares of company stock valued at $720,412. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.